Relevance of serologic studies in inflammatory bowel disease

被引：41

作者：

Vernier G. ^{[1
]}

Sendid B. ^{[1
]}

Poulain D. ^{[1
]}

Colombel J.-F. ^{[1
]}

机构：

[1] Service des Maladies, Appareil Digestif et de la Nutrition, CHRU Claude Huriez

来源：

Current Gastroenterology Reports | 2004年 / 6卷 / 6期

关键词：

Inflammatory Bowel Disease; Ulcerative Colitis; Celiac Disease; Indeterminate Colitis; Small Bowel Disease;

D O I：

10.1007/s11894-004-0070-x

中图分类号：

学科分类号：

摘要：

The serologic panel for inflammatory bowel disease (IBD) is rapidly expanding. Antineutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces cerevisiae mannan antibodies (ASCA) have remained the most widely studied markers, but immune reactivity against a new group of bacterial antigens such as 12, OmpC (outer membrane porin C), and flagellin, has been described in Crohn's disease. Several clinical avenues have been explored, such as the usefulness of serologic markers as screening tools for IBD and in accelerating a diagnosis in patients with indeterminate colitis. Another area of interest is disease stratification. Emerging data suggest there is a diversity of qualitative and quantitative responses to environmental antigens that differs among groups of IBD patients and may be associated with different clinical behaviors. As a result, it may be possible to tailor therapy on the basis of serologic responses. Prospective studies are needed before translating this concept into clinical practice. Clustering of IBD patients into more homogeneous subgroups based on antibody responses may help to unravel the pathophysiology of subsets of IBD. Copyright © 2004 by Current Science Inc.

引用

页码：482 / 487

页数：5

共 36 条

[11]

Damoiseaux J.G., Bouten B., Linders A.M., Et al., Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: High prevalence in patients with celiac disease, J. Clin. Immunol., 22, pp. 281-288, (2002)

[12]

Escher J.C., Serologic tests are helpful in managing but not in diagnosing IBD, Inflamm. Bowel Dis., 8, pp. 230-321, (2002)

[13]

Dubinsky M.C., Ofman J.J., Urman M., Et al., Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease, Am. J. Gastroenterol., 96, pp. 758-765, (2001)

[14]

Dubinsky M.C., Johanson J.F., Seidman E.G., Ofman J.J., Suspected inflammatory bowel disease: The clinical and economic impact of competing diagnostic strategies, Am. J. Gastroenterol., 97, pp. 2333-2342, (2002)

[15]

Khan K., Schwarzenberg S.J., Sharp H., Et al., Role of serology and routine laboratory tests in childhood inflammatory bowel disease, Inflamm. Bowel Dis., 8, pp. 325-329, (2002)

[16]

Gupta S.K., Fitzgerald J.F., Croffie J.M., Et al., Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children, Inflamm. Bowel Dis., 10, pp. 240-244, (2004)

[17]

Panaccione R., Sandborn W.J., Is antibody testing for inflammatory bowel disease clinically useful?, Gastroenterology, 116, pp. 1001-1002, (1999)

[18]

Joossens S., Reinisch W., Vermeire S., Et al., The value of serologic markers in indeterminate colitis: A prospective follow-up study, Gastroenterology, 122, pp. 1242-1247, (2002)

[19]

Plevy S., Do serological markers and cytokines determine the indeterminate?, J. Clin. Gastroenterol., 38, (2004)

[20]

Aisenberg J., Legnani P.E., Nilubol N., Et al., Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients, Am. J. Gastroenterol., 99, pp. 432-441, (2004)

← 1 2 3 4 →